Drugs / Liposomal Cytarabine-Daunorubicin CPX-351
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT01804101 | May 2013 → Jan 2017 | acute biphenotypic leukemia, myelodysplastic syndrome | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Liposomal Cytarabine-Daunorubicin CPX-351 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01804101 ↗ |
| Route | Intravenous | “Given IV” NCT01804101 ↗ |